Sutro Biopharma Stock (NASDAQ:STRO)
Previous Close
$3.55
52W Range
$2.01 - $6.13
50D Avg
$3.87
200D Avg
$4.03
Market Cap
$302.45M
Avg Vol (3M)
$595.60K
Beta
1.17
Div Yield
-
STRO Company Profile
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
STRO Performance
Peer Comparison
Ticker | Company |
---|---|
ANAB | AnaptysBio, Inc. |
IDYA | IDEAYA Biosciences, Inc. |
CNTA | Centessa Pharmaceuticals plc |
MRUS | Merus N.V. |
LRMR | Larimar Therapeutics, Inc. |
MLYS | Mineralys Therapeutics, Inc. |
MGTX | MeiraGTx Holdings plc |
HLVX | HilleVax, Inc. |
AVTE | Aerovate Therapeutics, Inc. |
REPL | Replimune Group, Inc. |
SNDX | Syndax Pharmaceuticals, Inc. |
KROS | Keros Therapeutics, Inc. |
GNTA | Genenta Science S.p.A. |
PCVX | Vaxcyte, Inc. |
FIXX | Q32 Bio Inc. |
PRDS | Pardes Biosciences, Inc. |
OPT | Opthea Limited |
ELYM | Eliem Therapeutics, Inc. |